We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
ImmuCell Swings to Q2 Profit on Strong Sales, Shares Still Slide
Read MoreHide Full Article
Shares of ImmuCell Corporation (ICCC - Free Report) have declined 7.4% since the company reported its earnings for the second quarter of 2025. This compares unfavorably with the S&P 500 index, which slipped just 0.8% during the same period. Over the past month, ImmuCell stock has dropped 11.5%, while the broader market posted a 1.8% gain, reflecting clear investor caution despite the company’s operational improvements.
ImmuCell posted second-quarter revenues of $6.4 million, up 18% from $5.5 million a year earlier. Net income swung to a profit of $502,000, or 6 cents per diluted share, compared to a net loss of $1.5 million, or 20 cents per share, in the prior-year quarter. For the first half of 2025, revenues grew 14% year over year to $14.5 million, and net income rose to $1.9 million, or 22 cents per share, compared to a $2 million loss in the prior-year period. The turnaround was supported by a significant gross margin improvement to 44% in the second quarter, up from 22% in the year-ago period.
ImmuCell Corporation Price, Consensus and EPS Surprise
ImmuCell highlighted a material improvement in operating performance. Adjusted EBITDA turned positive at $1.4 million for the quarter compared to a loss of $619,000 in the prior year. Over the trailing 12 months, adjusted EBITDA stood at $5.3 million, reversing a loss of $370,000 in the prior-year period.
Balance sheet strength also improved: cash and equivalents rose to $6 million from $3.8 million at year-end 2024, with net working capital at $12.7 million. Importantly, the company refinanced part of its bank debt during the quarter, extending maturities and reducing balloon payment risk.
ImmuCell: Management Commentary
Chief Executive Officer Michael Brigham emphasized that the company eliminated its backlog of orders by June 30, 2025 and rebuilt distributor inventories ahead of the typically softer third quarter. He also confirmed the company is now positioned to build inventory for the peak selling season later in the year. Chief Financial Officer Timothy Fiori underscored that gross margin gains were instrumental in swinging the company back to profitability. However, management acknowledged that restocking distributors provided a temporary lift to sales, suggesting softer revenue momentum in the second half of 2025.
Factors Influencing ICCC’s Headline Numbers
The recovery stemmed largely from expanded First Defense production capacity, which allowed the company to eliminate backlogs that had previously constrained growth. The First Defense line continues to benefit from strong demand in both dairy and beef segments, and new formats such as spray-dried colostrum were introduced during the quarter, with initial sales recorded.
On the other hand, the development of Re-Tain, ICCC’s novel mastitis treatment, continues to face regulatory and operational hurdles. While ImmuCell has initiated investigational product use trials to gather field data, commercial launch is delayed pending FDA approval and resolution of manufacturing partner compliance issues. Management stressed that all current Re-Tain inventory will be used in these studies and will not contribute to revenues.
Guidance by ImmuCell
ImmuCell did not provide formal financial guidance for the remainder of 2025. However, executives cautioned that distributor restocking in the first half is likely to have provided a one-time sales boost, suggesting softer performance in the near term. They also indicated that future expansion of First Defense capacity from $30 million to $40 million in annual revenue support remains on hold until cash flow visibility improves.
Other Developments at ICCC
During the quarter, ImmuCell completed refinancing of a portion of its bank debt, securing a new five-year note that extends repayment to 2030 and eliminates a $2 million balloon payment previously scheduled for 2026. Additionally, the company advanced plans to test market acceptance of Re-Tain with Michigan State University, reflecting management’s strategy of balancing reduced development spend with exploration of strategic partnerships for commercialization.
In short, ImmuCell delivered a meaningful turnaround in profitability on the back of strong sales growth, margin expansion and elimination of order backlogs. While the company is now better positioned operationally, investor sentiment remains cautious due to concerns over the sustainability of recent sales momentum and ongoing uncertainties surrounding Re-Tain’s path to approval and commercialization.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
ImmuCell Swings to Q2 Profit on Strong Sales, Shares Still Slide
Shares of ImmuCell Corporation (ICCC - Free Report) have declined 7.4% since the company reported its earnings for the second quarter of 2025. This compares unfavorably with the S&P 500 index, which slipped just 0.8% during the same period. Over the past month, ImmuCell stock has dropped 11.5%, while the broader market posted a 1.8% gain, reflecting clear investor caution despite the company’s operational improvements.
ImmuCell posted second-quarter revenues of $6.4 million, up 18% from $5.5 million a year earlier. Net income swung to a profit of $502,000, or 6 cents per diluted share, compared to a net loss of $1.5 million, or 20 cents per share, in the prior-year quarter. For the first half of 2025, revenues grew 14% year over year to $14.5 million, and net income rose to $1.9 million, or 22 cents per share, compared to a $2 million loss in the prior-year period. The turnaround was supported by a significant gross margin improvement to 44% in the second quarter, up from 22% in the year-ago period.
ImmuCell Corporation Price, Consensus and EPS Surprise
ImmuCell Corporation price-consensus-eps-surprise-chart | ImmuCell Corporation Quote
Other Key Business Metrics of ICCC
ImmuCell highlighted a material improvement in operating performance. Adjusted EBITDA turned positive at $1.4 million for the quarter compared to a loss of $619,000 in the prior year. Over the trailing 12 months, adjusted EBITDA stood at $5.3 million, reversing a loss of $370,000 in the prior-year period.
Balance sheet strength also improved: cash and equivalents rose to $6 million from $3.8 million at year-end 2024, with net working capital at $12.7 million. Importantly, the company refinanced part of its bank debt during the quarter, extending maturities and reducing balloon payment risk.
ImmuCell: Management Commentary
Chief Executive Officer Michael Brigham emphasized that the company eliminated its backlog of orders by June 30, 2025 and rebuilt distributor inventories ahead of the typically softer third quarter. He also confirmed the company is now positioned to build inventory for the peak selling season later in the year. Chief Financial Officer Timothy Fiori underscored that gross margin gains were instrumental in swinging the company back to profitability. However, management acknowledged that restocking distributors provided a temporary lift to sales, suggesting softer revenue momentum in the second half of 2025.
Factors Influencing ICCC’s Headline Numbers
The recovery stemmed largely from expanded First Defense production capacity, which allowed the company to eliminate backlogs that had previously constrained growth. The First Defense line continues to benefit from strong demand in both dairy and beef segments, and new formats such as spray-dried colostrum were introduced during the quarter, with initial sales recorded.
On the other hand, the development of Re-Tain, ICCC’s novel mastitis treatment, continues to face regulatory and operational hurdles. While ImmuCell has initiated investigational product use trials to gather field data, commercial launch is delayed pending FDA approval and resolution of manufacturing partner compliance issues. Management stressed that all current Re-Tain inventory will be used in these studies and will not contribute to revenues.
Guidance by ImmuCell
ImmuCell did not provide formal financial guidance for the remainder of 2025. However, executives cautioned that distributor restocking in the first half is likely to have provided a one-time sales boost, suggesting softer performance in the near term. They also indicated that future expansion of First Defense capacity from $30 million to $40 million in annual revenue support remains on hold until cash flow visibility improves.
Other Developments at ICCC
During the quarter, ImmuCell completed refinancing of a portion of its bank debt, securing a new five-year note that extends repayment to 2030 and eliminates a $2 million balloon payment previously scheduled for 2026. Additionally, the company advanced plans to test market acceptance of Re-Tain with Michigan State University, reflecting management’s strategy of balancing reduced development spend with exploration of strategic partnerships for commercialization.
In short, ImmuCell delivered a meaningful turnaround in profitability on the back of strong sales growth, margin expansion and elimination of order backlogs. While the company is now better positioned operationally, investor sentiment remains cautious due to concerns over the sustainability of recent sales momentum and ongoing uncertainties surrounding Re-Tain’s path to approval and commercialization.